Vanda Pharmaceuticals Inc (NASDAQ: VNDA) on Monday, soared 4.08% from the previous trading day, before settling in for the closing price of $4.66. Within the past 52 weeks, VNDA’s price has moved between $3.30 and $6.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 1.11% over the last five years. The company achieved an average annual earnings per share of -1300.00%. With a float of $55.19 million, this company’s outstanding shares have now reached $57.53 million.
The firm has a total of 203 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.95%, operating margin of -17.84%, and the pretax margin is -6.57%.
Vanda Pharmaceuticals Inc (VNDA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Vanda Pharmaceuticals Inc is 5.31%, while institutional ownership is 75.13%. The most recent insider transaction that took place on Jul 29 ’24, was worth 13,327. In this transaction SVP, CFO & Treasurer of this company sold 2,251 shares at a rate of $5.92, taking the stock ownership to the 228,763 shares. Before that another transaction happened on Jul 29 ’24, when Company’s Officer proposed sale 2,251 for $5.92, making the entire transaction worth $13,327.
Vanda Pharmaceuticals Inc (VNDA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -1300.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 36.10% during the next five years compared to -37.98% drop over the previous five years of trading.
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) Trading Performance Indicators
Vanda Pharmaceuticals Inc (VNDA) is currently performing well based on its current performance indicators. A quick ratio of 4.67 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.19, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach 0.02 in one year’s time.
Technical Analysis of Vanda Pharmaceuticals Inc (VNDA)
Analysing the last 5-days average volume posted by the [Vanda Pharmaceuticals Inc, VNDA], we can find that recorded value of 0.45 million was lower than the volume posted last year of 1.32 million. As of the previous 9 days, the stock’s Stochastic %D was 61.67%. Additionally, its Average True Range was 0.19.
During the past 100 days, Vanda Pharmaceuticals Inc’s (VNDA) raw stochastic average was set at 20.83%, which indicates a significant decrease from 74.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.19% in the past 14 days, which was lower than the 45.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.82, while its 200-day Moving Average is $4.88. Now, the first resistance to watch is $4.94. This is followed by the second major resistance level at $5.03. The third major resistance level sits at $5.18. If the price goes on to break the first support level at $4.70, it is likely to go to the next support level at $4.56. Should the price break the second support level, the third support level stands at $4.47.
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) Key Stats
Market capitalization of the company is 283.31 million based on 58,290K outstanding shares. Right now, sales total 192,640 K and income totals 2,510 K. The company made 50,470 K in profit during its latest quarter, and -4,520 K in sales during its previous quarter.
